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Abstract 
Background: In the era of intensity‑modulated radiotherapy (IMRT), the role of neoadjuvant chemotherapy (NACT) in 
treating ascending‑type nasopharyngeal carcinoma (NPC) is under‑evaluated. This study was to compare the efficacy of 
NACT followed by IMRT (NACT + RT) with the efficacy of concurrent chemoradiotherapy (CCRT) on ascending‑type NPC.
Methods: Clinical data of 214 patients with ascending‑type NPC treated with NACT + RT or CCRT between Decem‑
ber 2009 and July 2011 were analyzed. Of the 214 patients, 98 were treated with NACT followed by IMRT, and 116 
were treated with CCRT. The survival rates were assessed using Kaplan–Meier analysis, and the survival curves were 
compared using a log‑rank test.
Results: The 4‑year overall survival, locoregional failure‑free survival, distant failure‑free survival, and failure‑free sur‑
vival rates were not significantly different between the two groups (all P > 0.05). However, patients in the CCRT group 
exhibited more severe acute adverse events than did patients in the NACT + RT group during radiotherapy, includ‑
ing leukopenia (30.2% vs. 15.3%, P = 0.016), neutropenia (25.9% vs. 11.2%, P = 0.011), and mucositis (57.8% vs. 40.8%, 
P = 0.028). After radiotherapy, patients in the CCRT group exhibited significantly higher rates of xerostomia (21.6% vs. 
10.2%, P = 0.041) and hearing loss (17.2% vs. 6.1%, P = 0.023).
Conclusions: The treatment outcomes of the NACT + RT and CCRT groups were similar; however, CCRT led to higher 
rates of acute and late toxicities. NACT + RT may therefore be a better treatment strategy for ascending‑type NPC.
Keywords: Nasopharyngeal carcinoma, Ascending‑type, Intensity‑modulated radiotherapy, Neoadjuvant 
chemotherapy, Concurrent chemoradiotherapy
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Background
Nasopharyngeal carcinoma (NPC) is a common dis-
ease in South China [1]. In contrast to patients with 
early-stage NPC, who have 5-year overall survival (OS) 
rates of up to 95% [2–4], the 5-year OS rate declines to 
41%–63% in patients with advanced-stage disease [5, 6]. 
Thus, there is a clear need to improve the treatment out-
come for advanced-stage NPC.
Previous publications [7, 8] and meta-analyses [9, 10] 
have reported that concurrent chemoradiotherapy (CCRT) 
provides greater survival benefits than neoadjuvant chem-
otherapy (NACT) followed by radiotherapy. Additionally, 
a clinical trial [11] and a meta-analysis [12] found that 
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NACT followed by CCRT was well tolerated and provided 
good outcomes, whereas others [13–15] question the value 
of concurrent chemotherapy for intensity-modulated 
radiotherapy (IMRT)-treated patients with locoregionally 
advanced NPC. These discrepancies may be partly due to 
the biological heterogeneity of NPC cases in the study pop-
ulations. As reported by Wee et al. [16], NPC patients with 
predominantly advanced local disease (advanced T stage) 
and early-stage cervical lymph node involvement (early N 
stage) are classified as having the ascending type of the dis-
ease, who usually experiences local failure, whereas those 
with early-stage local disease (early T stage) and advanced 
lymph node metastases (advanced N stage) are classified 
as having the descending type, for whom distant failure is 
more common than local failure. These two types of NPC 
can exhibit distinct clinical-biological behaviors [17].
These previous studies did not take tumor heteroge-
neity into account, and differences in the numbers of 
cases of the ascending and descending types in the study 
populations could have affected the conclusions. There-
fore, we included only ascending-type NPC cases in our 
study to avoid the effect of such tumor heterogeneity. The 
objective of the present study was to assess the efficacy 
of NACT followed by IMRT (NACT + RT) versus con-




Consecutive patients with newly diagnosed, histologically 
proven, non-distant metastatic, ascending-type NPC that 
was treated with IMRT between December 2009 and 
July 2011 at the Sun Yat-sen University Cancer Center 
(Guangzhou, China) were selected. The need for written 
consent was waived, whereas oral consent was obtained 
from the patients via telephone, as documented by tel-
ephone recording. The use of oral consent was approved 
by the institutional review board.
All patients completed a pretreatment evaluation, 
which included physical examination, chest radiography, 
nasopharyngeal and neck magnetic resonance imaging 
(MRI), abdominal sonography, and a whole-body bone 
scan. Patients were restaged by two radiation oncolo-
gists specializing in head and neck cancer according to 
the 7th edition of the Union for International Cancer 
Control/American Joint Committee on Cancer (UICC/
AJCC) staging system, with disagreements resolved by 
consensus.
Radiotherapy
The primary tumor and the upper neck area above the 
caudal edge of the cricoid cartilage were treated with 
IMRT. Target volumes were delineated according to our 
institutional treatment protocol [18], in agreement with 
the International Commission on Radiation Units and 
Measurements (ICRU) Reports 62 [19] and 83 [20]. The 
gross tumor volume (GTV) including primary naso-
pharyngeal tumor (GTVp) and involved lymph nodes 
(GTVnd) was delineated on the basis of physical exami-
nation and MRI findings. Gross disease at primary site 
together with enlarged retropharyngeal lymph nodes 
was designated GTVp; clinically-involved cervical lymph 
nodes, GTVnd. Two clinical target volumes (CTVs) 
were delineated according to the GTV: CTV1, high-risk 
regions encompassing GTVp plus 5–10  mm, including 
the entire nasopharyngeal mucosa and 5-mm submucosal 
region; and CTV2, low-risk regions containing CTV1 
plus 5–10 mm, encompassing sites of microscopic exten-
sion and lymphatic regions. The planning target volumes 
(PTVs), termed PTVp, PTV1, PTV2, and PTVnd, were 
constructed by expanding the GTVp, CTV1, CTV2, and 
CTVnd, respectively, by 3 mm; a 3 mm margin was added 
to the brainstem and spinal cord to generate planning 
organ at risk volume (PRV).
The prescribed doses to PTVp, PTVnd, PTV1, and 
PTV2 were 66–72, 64–70, 60–63, and 54–56  Gy, 
respectively, in 28–33 fractions (66–70  Gy to PTVp 
for T1 NPC and 68–72  Gy for T2-4 NPC; 68–70  Gy 
to clinically-involved nodes >1  cm in diameter and 
64–68 Gy to nodes ≤1 cm in diameter) [21]. The dose 
constraints for organs at risk (OARs) and PRVs were as 
described in the Radiation Therapy Oncology Group 
(RTOG)-0225 trial [22]. All patients were treated fol-
lowing a routine schedule (one fraction daily for 5 days 
per week).
Boost treatment was offered for selected patients at the 
attending physician’s discretion, usually in cases of bulky 
or suspected residual disease. This additional radiation 
was delivered by high-dose-rate intracavitary brachyther-
apy or external beam radiation.
Chemotherapy
During the study period, institutional guidelines recom-
mended neoadjuvant or adjuvant chemotherapy and/
or CCRT for stage III to IVA-B NPC. For these patients, 
NACT was given when it was considered advantageous 
to reduce bulky tumors or when the waiting time for 
radiotherapy was considered to be longer than accept-
able. The NACT consisted of cisplatin (80–100  mg/
m2, intravenous infusion on day 1) plus 5-fluorouracil 
(800–1000  mg/m2, 120-h continuous intravenous infu-
sion) or cisplatin (80–100  mg/m2, intravenous infusion 
on day 1) plus docetaxel (60–80 mg/m2, intravenous infu-
sion on day 1) every 3  weeks for three cycles. Concur-
rent chemotherapy consisted of cisplatin (80–100 mg/m2, 
intravenous infusion on day 1) given in weeks 1, 4, and 
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7 of radiotherapy or cisplatin (30–45 mg/m2, intravenous 
infusion on day 1) given weekly during radiotherapy. 
Deviations from the institutional guidelines were due to 
organ dysfunction (suggesting intolerance to the chemo-
therapy) or patient refusal.
Patient assessment and follow‑up
Our primary study endpoint was OS, defined as the dura-
tion from the date of treatment initiation to the date of 
cancer-related death or the last follow-up. The second-
ary endpoints included locoregional failure-free survival 
(LRFFS), defined as the duration from the date of treat-
ment initiation to the date of the first relapse in the naso-
pharyngeal and/or cervical region or the last follow-up; 
distant failure-free survival (DFFS), defined as the dura-
tion from the date of treatment initiation to the date 
of the first distant metastasis or the last follow-up; and 
failure-free survival (FFS), defined as the duration from 
the date of treatment initiation to the date of disease pro-
gression (local/regional recurrence or distant metastasis), 
death from any cause, or the last follow-up. Acute and 
late toxicities were documented according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE) 
version 3.0 and/or the Radiation Morbidity Scoring Cri-
teria of the RTOG.
The last follow-up visit was in November 2015. 
Patients were assessed at least every 3  months in the 
first 3  years and every 6  months thereafter. Routine 
follow-up included complete head and neck examina-
tion, nasopharyngoscopy, hematology and biochemistry 
profiles, chest radiography, and abdominal sonography. 
Follow-up neck and/or nasopharyngeal MRI was per-
formed every 6–12  months, especially for patients with 
suspected tumor recurrence or radiotherapy-induced 
complications.
Statistical analysis
To compare clinicopathologic features between the 
NACT  +  RT and CCRT groups, a Chi square (χ2) test 
was used for categorical variables, and a Kruskal–Wal-
lis rank-sum test was used for continuous variables. The 
Kaplan–Meier method was used to estimate the rates of 
OS, LRFFS, DFFS, and FFS. The log-rank test was used to 
compare the survival rates between the NACT + RT and 
CCRT groups. All statistical tests were two-sided, and 
P < 0.05 was considered statistically significant. Statistical 
analyses were performed with R version 3.1.2.
Results
Patient characteristics
Between December 2009 and July 2011, 239 consecutive 
patients with ascending-type NPC were treated at our 
center. Of the 239 patients, 25 were excluded: 6 received 
adjuvant chemotherapy, 8 received both NACT and con-
current chemotherapy, and 11 received radiotherapy 
alone. Therefore, a total of 214 patients were included 
in the study: 98 were treated with NACT + RT, and 116 
were treated with CCRT.
All patients had biopsy-proven NPC and an adequate 
performance status for radical treatment (Karnofsky per-
formance score ≥70). Clinicopathologic features were 
well balanced between the two groups (Table  1), and 
there were no significant differences in the radiother-
apy dose or duration. The median follow-up period was 
46.8 months (range 8.9–70.3 months).
Treatment compliance
All patients completed the planned course of IMRT. 
Six patients received boost treatment after the planned 
course of IMRT due to the presence of gross residual 
disease (i.e., <100% resolution of the primary disease), as 
observed on follow-up MRI, or nasopharyngoscopy. Of 
these patients, four were treated with a brachytherapy 
boost (12–16 Gy at 3–4 Gy per daily fraction), and two 
Table 1 Clinicopathologic features of  the neoadjuvant 
chemotherapy plus radiotherapy (NACT + RT) group and the 
concurrent chemoradiotherapy (CCRT) group of  patients 
with ascending-type nasopharyngeal carcinoma (NPC)
WHO World Health Organization
a According to the Union for International Cancer Control/American Joint 
Committee on Cancer staging system, 7th edition
Variable NACT + RT group CCRT group P value
Total 98 116
Age (years) 0.367
 Median 44 45
 Range 17–70 16–70
Gender [cases (%)] 0.179
 Male 84 (85.7) 90 (77.6)
 Female 14 (14.3) 26 (22.4)
Histology [cases (%)] 0.795
 WHO II 5 (5.1) 8 (6.9)
 WHO III 93 (94.9) 108 (93.1)
T stage [cases (%)]a 0.131
 T3 43 (43.9) 64 (55.2)
 T4 55 (56.1) 52 (44.8)
N stage [cases (%)]a 0.118
 N0 34 (34.7) 47 (40.5)
 N1 64 (65.3) 69 (59.5)
Total radiation dose (Gy) 0.721
 Median 70 69
 Range 66–72 66–72
Overall duration of radiotherapy (days) 0.674
 Median 46 47
 Range 40–49 42–51
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were treated with external beam irradiation (11  Gy at 
2.2 Gy per daily fraction).
In the NACT +  RT group, 42 patients were treated 
with a PF regimen (cisplatin and 5-fluorouracil), and 
56 patients were treated with a TP regimen (cisplatin 
and docetaxel). Six patients (6.1%) in the NACT + RT 
group completed only one cycle of NACT: 1 developed 
febrile neutropenia, 2 exhibited impaired liver func-
tion, and 3 refused further chemotherapy. The other 92 
patients (93.9%) in the NACT +  RT group completed 
2–3 cycles of NACT. In the CCRT group, 58 patients 
(50.0%) were treated with cisplatin every 3 weeks dur-
ing radiotherapy, and the other 58 (50.0%) were treated 
with weekly cisplatin during radiotherapy. Of those 
who were treated with cisplatin every 3  weeks, 44 
(75.9%) completed two cycles, and 14 (24.1%) com-
pleted three cycles. Of those who were treated with 
weekly cisplatin, 52 (89.6%) completed at least four 
cycles. The median doses of cisplatin were 185  mg/
m2 for the NACT + RT group and 200 mg/m2 for the 
CCRT group.
Acute and late toxicities
In the NACT  +  RT group, among the severe to life-
threatening (grade 3–4) hematologic adverse events that 
were observed during NACT, neutropenia was the most 
common (24 patients; 24.5%), and the most common 
non-hematologic adverse event was nausea/vomiting (6 
patients; 6.1%). Other grade 3–4 acute adverse events 
included leukopenia, thrombocytopenia, hepatotoxicity, 
and nephrotoxicity (Table 2).
Acute toxicities during radiotherapy were well toler-
ated by both groups. During radiotherapy, the rates of 
grade 3–4 adverse events were higher in the CCRT group 
than in the NACT  +  RT group (mucositis: 57.8% vs. 
40.8%, P = 0.028; leukopenia: 30.2% vs. 15.3%, P = 0.016; 
and neutropenia: 25.9% vs. 11.2%, P = 0.011) (Table 2).
Common late adverse events included xerostomia, 
hearing loss, neuropathy, and neck tissue damage. The 
rates of grade 3–4 xerostomia and hearing loss were sig-
nificantly lower in the NACT  +  RT group than in the 
CCRT group (10.2% vs. 21.6%, P = 0.041; 6.1% vs. 17.2%, 
P  =  0.023). The rates of all other adverse events were 
Table 2 Acute and late adverse events in the NACT + RT and CCRT groups
Comparison of the incidence of grade 3–4 events between the two groups
NA not applicable
† P values were calculated using a Chi square test
Adverse event NACT + RT group [cases (%)] CCRT group [cases (%)] P 
value†
Grade 1–4 Grade 3–4 Grade 1–4 Grade 3–4
Neoadjuvant phase
 Neutropenia 61 (62.2) 24 (24.5) NA NA NA
 Leukopenia 54 (55.1) 20 (20.4) NA NA NA
 Thrombocytopenia 11 (11.2) 4 (4.1) NA NA NA
 Nausea/vomiting 47 (48.0) 6 (6.1) NA NA NA
 Hepatotoxicity 53 (54.1) 3 (3.1) NA NA NA
 Nephrotoxicity 37 (37.8) 1 (1.0) NA NA NA
Irradiation phase
 Mucositis 98 (100) 40 (40.8) 116 (100) 67 (57.8) 0.028
 Xerostomia 98 (100) 24 (24.5) 116 (100) 35 (30.2) 0.439
 Skin 98 (100) 11 (11.2) 116 (100) 19 (16.4) 0.376
 Nausea/vomiting 41 (41.8) 7 (7.1) 68 (58.6) 10 (8.6) 0.885
 Leukopenia 43 (43.9) 15 (15.3) 71 (61.2) 35 (30.2) 0.016
 Neutropenia 36 (36.7) 11 (11.2) 75 (64.7) 30 (25.9) 0.011
 Thrombocytopenia 15 (15.3) 3 (3.1) 24 (20.7) 7 (6.0) 0.157
 Hepatotoxicity 28 (28.6) 1 (1.0) 40 (34.5) 2 (1.7) 0.864
 Nephrotoxicity 22 (22.4) 0 (0) 32 (27.6) 0 (0) 0.789
Post‑irradiation phase
 Xerostomia 98 (100) 10 (10.2) 116 (100) 25 (21.6) 0.041
 Hearing loss 34 (34.7) 6 (6.1) 69 (59.5) 20 (17.2) 0.023
 Neuropathy 24 (24.5) 2 (2.0) 37 (31.9) 1 (0.9) 0.761
 Neck tissue damage 9 (9.2) 0 (0) 15 (12.9) 0 (0) 0.867
 Dysphagia 1 (1.0) 0 (0) 2 (1.7) 0 (0) 0.998
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not significantly different between the two groups (all 
P > 0.05) (Table 2).
Treatment outcomes
The 4-year OS rates were 92.3% in the NACT  +  RT 
group and 82.1% in the CCRT group (Fig.  1a). The two 
groups had a similar risk of death (HR  =  0.41; 95% CI 
0.16–1.12; P = 0.072). The 4-year LRFFS rates were 87.2% 
in the NACT + RT group and 79.5% in the CCRT group 
(Fig.  1b), and the HR for the treatment effect was 0.66 
(95% CI 0.32–1.38; P =  0.268). Fourteen patients in the 
NACT  +  RT group and 25 in the CCRT group devel-
oped locoregional failure. The 4-year DFFS rates were 
84.7% in the NACT + RT group and 81.4% in the CCRT 
group (Fig. 1c), and the HR for the treatment effect was 
0.77 (95% CI 0.33–1.78; P = 0.539). Thirteen patients in 
the NACT + RT group and 23 in the CCRT group devel-
oped distant metastases. The 4-year FFS rates were 76.3% 
in the NACT + RT group and 73.2% in the CCRT group 
(Fig.  1d), and the HR for the treatment effect was 0.70 
(95% CI 0.37–1.36; P =  0.293). Twenty-four patients in 
the NACT + RT group and 32 in the CCRT group devel-
oped locoregional failure and/or distant metastases.
Discussion
In the current study, we retrospectively compared the 
efficacy of NACT  +  RT with the efficacy of CCRT 
on ascending-type NPC. The results showed that 
NACT + RT for ascending-type NPC provided a favora-
ble outcome in terms of 4-year OS, LRFFS, DFFS, and 
FFS rates. In consistent with our results, Lin et  al. [15] 
and Qiu et al. [23] investigated patients with locoregion-
ally advanced NPC who were treated with IMRT after 
NACT and demonstrated that NACT + RT produced a 
superb outcome in terms of OS, LRFFS, DFFS, and FFS 
rates in these patients. Our results further suggested that 
CCRT offered no significant survival benefit when com-
pared with NACT + RT.
The treatment outcome with the application of IMRT 
has been demonstrated in terms of locoregional control 
in NPC patients [24]. The 3-year LRFFS and OS rates of 
NPC patients were 90%–95% and 80%–85%, respectively 
Fig. 1 Kaplan–Meier estimates of the survival of patients with the ascending type of nasopharyngeal carcinoma (NPC) treated with neoadjuvant 
chemotherapy plus subsequent radiotherapy (NACT + RT) or with concurrent chemoradiotherapy (CCRT). a Overall survival; b locoregional failure‑
free survival; c distant failure‑free survival; d failure‑free survival
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[25–28]. Improved locoregional control was anticipated 
with improved dose coverage of GTV and CTV. There-
fore, the effect of chemotherapy on locoregional control 
in NPC patients treated with IMRT remained uncer-
tain. Our results demonstrated that for patients with 
ascending-type NPC, CCRT provided no significant 
improvement in terms of LRFFS when compared with 
NACT + RT; the 4-year LRFFS rate was, in fact, higher 
in the NACT + RT group (87.2% vs. 79.5%), though the 
difference was not significant (P = 0.268). Lai et al. [29] 
found that LRFFS was significantly longer for patients 
who underwent IMRT than for patients who underwent 
two-dimensional conventional radiotherapy (2D-CRT). 
Compared with 2D-CRT, IMRT generates more confor-
mal dose coverage in the target volume and therefore 
results in better local control. Thus, it is possible that the 
improved local control rates obtained with IMRT elimi-
nated the contribution of concurrent chemotherapy to 
LRFFS. Furthermore, significant NACT-induced shrink-
age of the tumor prior to radiotherapy increases the mar-
gin of safety between the tumor and irradiation volumes, 
as reported by Teo et  al. [30], which could reduce the 
locoregional recurrence rate in patients with locoregion-
ally advanced NPC.
Although the main advantage of NACT is reduction of 
distant metastases [31], the NACT + RT group did not 
exhibit a significantly lower rate of distant metastases 
compared with the CCRT group in the present study. This 
observation may be interpreted as follows. First, the ten-
dency in this study was to give NACT to patients when it 
was considered advantageous to reduce bulky tumors or 
when the waiting time for radiotherapy was considered 
to be longer than acceptable. For those patients, tumor 
volumes were relatively large despite the same T stage. 
However, previous studies have revealed that the primary 
tumor volume is closely related to disease progression in 
NPC [32, 33]. Guo et  al. [34] demonstrated that a large 
tumor volume was predictive of a poor prognosis and 
was associated with distant metastasis in NPC patients 
treated with IMRT. Second, this analysis may have been 
affected by the smaller size of the NACT  +  RT group 
compared with that of the CCRT group [98 (45.8%) vs. 
116 (54.2%)].
Clearly, treatment-induced adverse events could limit 
efficacy in patients with locoregionally advanced NPC. 
In this study, specific adverse events were associated 
with each of the two treatment protocols. Compared 
with the NACT +  RT group, the CCRT group suffered 
significantly more acute adverse events such as neutro-
penia, leukopenia, and mucositis during radiotherapy. 
These findings are consistent with those reported in pre-
vious studies that used similar irradiation techniques [35, 
36]. There was also a significant difference between our 
two groups in terms of late adverse events: patients in the 
CCRT group exhibited significantly more xerostomia and 
hearing loss than patients in the NACT + RT group. Two 
underlying reasons for these findings could be as follows: 
first, concurrent chemotherapy may increase the sensitiv-
ity of normal tissue to radiotherapy-related injury, and 
second, the total radiation dose to nearby organs may be 
reduced after the primary tumor has been shrunken by 
NACT.
Compared with the CCRT group in the present 
study, Kong et  al. [37] showed lower rates of severe 
irradiation-related mucositis and xerostomia in 
advanced NPC patients treated with NACT +  CCRT. 
In the current study, only the patients with ascend-
ing-type NPC, predominantly advanced local disease 
(T3-4) with early-stage cervical lymph node involve-
ment (N0-1), were selected, whereas Kong et  al. [37] 
did not take into account the variability of the tumor 
itself. With ascending-type NPC, patients have high 
radiation doses to OARs due to the advanced T stage 
and large target volume. For example, despite the same 
stage (stage IV) and the same treatment for patients 
with T1N3 and T4N0 NPC, the adverse events might 
be markedly different.
Conclusions
Compared with NACT + RT, CCRT did not significantly 
increase the 4-year OS, LRFFS, and FFS rates of patients 
with ascending-type NPC, and CCRT was associated 
with higher rates of severe adverse events. These results 
suggest that NACT + RT may be a more suitable treat-
ment strategy for ascending-type NPC. However, our 
study was limited by the small sample size and the use 
of retrospective analysis. A prospective randomized trial 
will be needed to confirm the findings.
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